# A Multi-Scale Graph Neural Process with Cross-Drug Co-Attention for Drug-Drug Interactions Prediction

**Korean Title:** ë‹¤ì¤‘ ìŠ¤ì¼€ì¼ ê·¸ë˜í”„ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ì™€ êµì°¨ ì•½ë¬¼ ê³µë™ ì£¼ì˜ ë©”ì»¤ë‹ˆì¦˜ì„ í†µí•œ ì•½ë¬¼ ìƒí˜¸ì‘ìš© ì˜ˆì¸¡

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily/2025-09-22|2025-09-22]] [[categories/cs.AI|cs.AI]]

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸš€ Evolved Concepts**: Multi-scale Graph Representation

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[2025-09-18/Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery_20250918|Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery]] (83.0% similar)
- [[2025-09-18/Locally Explaining Prediction Behavior via Gradual Interventions and Measuring Property Gradients_20250918|Locally Explaining Prediction Behavior via Gradual Interventions and Measuring Property Gradients]] (77.8% similar)
- [[2025-09-19/DINAMO_ Dynamic and INterpretable Anomaly MOnitoring for Large-Scale Particle Physics Experiments_20250919|DINAMO Dynamic and INterpretable Anomaly MOnitoring for Large-Scale Particle Physics Experiments]] (77.7% similar)
- [[2025-09-18/Semi-Supervised 3D Medical Segmentation from 2D Natural Images Pretrained Model_20250918|Semi-Supervised 3D Medical Segmentation from 2D Natural Images Pretrained Model]] (77.4% similar)
- [[2025-09-17/A Conformal Prediction Framework for Uncertainty Quantification in Physics-Informed Neural Networks_20250917|A Conformal Prediction Framework for Uncertainty Quantification in Physics-Informed Neural Networks]] (77.2% similar)

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2509.15256v1 Announce Type: cross 
Abstract: Accurate prediction of drug-drug interactions (DDI) is crucial for medication safety and effective drug development. However, existing methods often struggle to capture structural information across different scales, from local functional groups to global molecular topology, and typically lack mechanisms to quantify prediction confidence. To address these limitations, we propose MPNP-DDI, a novel Multi-scale Graph Neural Process framework. The core of MPNP-DDI is a unique message-passing scheme that, by being iteratively applied, learns a hierarchy of graph representations at multiple scales. Crucially, a cross-drug co-attention mechanism then dynamically fuses these multi-scale representations to generate context-aware embeddings for interacting drug pairs, while an integrated neural process module provides principled uncertainty estimation. Extensive experiments demonstrate that MPNP-DDI significantly outperforms state-of-the-art baselines on benchmark datasets. By providing accurate, generalizable, and uncertainty-aware predictions built upon multi-scale structural features, MPNP-DDI represents a powerful computational tool for pharmacovigilance, polypharmacy risk assessment, and precision medicine.

## ğŸ” Abstract (í•œê¸€ ë²ˆì—­)

arXiv:2509.15256v1 ë°œí‘œ ìœ í˜•: êµì°¨  
ì´ˆë¡: ì•½ë¬¼ ìƒí˜¸ì‘ìš©(DDI)ì˜ ì •í™•í•œ ì˜ˆì¸¡ì€ ì•½ë¬¼ ì•ˆì „ì„±ê³¼ íš¨ê³¼ì ì¸ ì•½ë¬¼ ê°œë°œì— í•„ìˆ˜ì ì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ê¸°ì¡´ ë°©ë²•ë“¤ì€ ì¢…ì¢… êµ­ì†Œ ê¸°ëŠ¥ ê·¸ë£¹ì—ì„œ ì „ì—­ ë¶„ì ìœ„ìƒì— ì´ë¥´ëŠ” ë‹¤ì–‘í•œ ê·œëª¨ì˜ êµ¬ì¡°ì  ì •ë³´ë¥¼ í¬ì°©í•˜ëŠ” ë° ì–´ë ¤ì›€ì„ ê²ªìœ¼ë©°, ì˜ˆì¸¡ ì‹ ë¢°ë„ë¥¼ ì •ëŸ‰í™”í•  ìˆ˜ ìˆëŠ” ë©”ì»¤ë‹ˆì¦˜ì´ ë¶€ì¡±í•œ ê²½ìš°ê°€ ë§ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í•œê³„ë¥¼ ê·¹ë³µí•˜ê¸° ìœ„í•´, ìš°ë¦¬ëŠ” MPNP-DDIë¼ëŠ” ìƒˆë¡œìš´ ë‹¤ì¤‘ ê·œëª¨ ê·¸ë˜í”„ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•©ë‹ˆë‹¤. MPNP-DDIì˜ í•µì‹¬ì€ ë…íŠ¹í•œ ë©”ì‹œì§€ ì „ë‹¬ ë°©ì‹ìœ¼ë¡œ, ì´ë¥¼ ë°˜ë³µì ìœ¼ë¡œ ì ìš©í•˜ì—¬ ì—¬ëŸ¬ ê·œëª¨ì—ì„œ ê·¸ë˜í”„ í‘œí˜„ì˜ ê³„ì¸µ êµ¬ì¡°ë¥¼ í•™ìŠµí•©ë‹ˆë‹¤. ì¤‘ìš”í•œ ê²ƒì€, êµì°¨ ì•½ë¬¼ ê³µë™ ì£¼ì˜ ë©”ì»¤ë‹ˆì¦˜ì´ ì´ëŸ¬í•œ ë‹¤ì¤‘ ê·œëª¨ í‘œí˜„ì„ ë™ì ìœ¼ë¡œ ìœµí•©í•˜ì—¬ ìƒí˜¸ì‘ìš©í•˜ëŠ” ì•½ë¬¼ ìŒì— ëŒ€í•œ ë§¥ë½ ì¸ì‹ ì„ë² ë”©ì„ ìƒì„±í•˜ë©°, í†µí•©ëœ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ ëª¨ë“ˆì´ ì›ì¹™ì ì¸ ë¶ˆí™•ì‹¤ì„± ì¶”ì •ì„ ì œê³µí•©ë‹ˆë‹¤. ê´‘ë²”ìœ„í•œ ì‹¤í—˜ ê²°ê³¼, MPNP-DDIê°€ ë²¤ì¹˜ë§ˆí¬ ë°ì´í„°ì…‹ì—ì„œ ìµœì²¨ë‹¨ ê¸°ì¤€ì„ í¬ê²Œ ëŠ¥ê°€í•¨ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë‹¤ì¤‘ ê·œëª¨ êµ¬ì¡°ì  íŠ¹ì§•ì— ê¸°ë°˜í•œ ì •í™•í•˜ê³  ì¼ë°˜í™” ê°€ëŠ¥í•˜ë©° ë¶ˆí™•ì‹¤ì„±ì„ ì¸ì‹í•˜ëŠ” ì˜ˆì¸¡ì„ ì œê³µí•¨ìœ¼ë¡œì¨, MPNP-DDIëŠ” ì•½ë¬¼ ê°ì‹œ, ë‹¤ì•½ì œ ìœ„í—˜ í‰ê°€, ì •ë°€ ì˜í•™ì„ ìœ„í•œ ê°•ë ¥í•œ ê³„ì‚° ë„êµ¬ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.

## ğŸ“ ìš”ì•½

ì´ ë…¼ë¬¸ì€ ì•½ë¬¼ ê°„ ìƒí˜¸ì‘ìš©(DDI) ì˜ˆì¸¡ì˜ ì •í™•ì„±ì„ ë†’ì´ê¸° ìœ„í•´ MPNP-DDIë¼ëŠ” ìƒˆë¡œìš´ ë‹¤ì¤‘ ìŠ¤ì¼€ì¼ ê·¸ë˜í”„ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•©ë‹ˆë‹¤. MPNP-DDIëŠ” ë…íŠ¹í•œ ë©”ì‹œì§€ ì „ë‹¬ ë°©ì‹ì„ í†µí•´ ë‹¤ì–‘í•œ ìŠ¤ì¼€ì¼ì—ì„œ ê·¸ë˜í”„ í‘œí˜„ì„ í•™ìŠµí•˜ë©°, êµì°¨ ì•½ë¬¼ ê³µë™ ì£¼ì˜ ë©”ì»¤ë‹ˆì¦˜ì„ í†µí•´ ë¬¸ë§¥ ì¸ì‹ ì„ë² ë”©ì„ ìƒì„±í•©ë‹ˆë‹¤. ë˜í•œ, í†µí•©ëœ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ ëª¨ë“ˆë¡œ ì˜ˆì¸¡ì˜ ë¶ˆí™•ì‹¤ì„±ì„ ì •ëŸ‰í™”í•©ë‹ˆë‹¤. ì‹¤í—˜ ê²°ê³¼, MPNP-DDIëŠ” ê¸°ì¡´ ë°©ë²•ë“¤ë³´ë‹¤ ë›°ì–´ë‚œ ì„±ëŠ¥ì„ ë³´ì˜€ìœ¼ë©°, ì•½ë¬¼ ê°ì‹œ, ë‹¤ì•½ì œ ìœ„í—˜ í‰ê°€, ì •ë°€ ì˜í•™ì— ìœ ìš©í•œ ë„êµ¬ë¡œ í™œìš©ë  ìˆ˜ ìˆìŒì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. MPNP-DDIëŠ” ì•½ë¬¼ ìƒí˜¸ì‘ìš© ì˜ˆì¸¡ì„ ìœ„í•´ ë‹¤ì¤‘ ìŠ¤ì¼€ì¼ ê·¸ë˜í”„ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•©ë‹ˆë‹¤.

- 2. ì´ í”„ë ˆì„ì›Œí¬ëŠ” ë©”ì‹œì§€ ì „ë‹¬ ë°©ì‹ì„ í†µí•´ ë‹¤ì–‘í•œ ìŠ¤ì¼€ì¼ì˜ ê·¸ë˜í”„ í‘œí˜„ì„ í•™ìŠµí•©ë‹ˆë‹¤.

- 3. êµì°¨ ì•½ë¬¼ ê³µë™ ì£¼ì˜ ë©”ì»¤ë‹ˆì¦˜ì„ í†µí•´ ë‹¤ì¤‘ ìŠ¤ì¼€ì¼ í‘œí˜„ì„ ë™ì ìœ¼ë¡œ ìœµí•©í•˜ì—¬ ë¬¸ë§¥ ì¸ì‹ ì„ë² ë”©ì„ ìƒì„±í•©ë‹ˆë‹¤.

- 4. í†µí•©ëœ ì‹ ê²½ í”„ë¡œì„¸ìŠ¤ ëª¨ë“ˆì€ ì˜ˆì¸¡ì˜ ë¶ˆí™•ì‹¤ì„±ì„ ì •ëŸ‰í™”í•˜ëŠ” ê¸°ëŠ¥ì„ ì œê³µí•©ë‹ˆë‹¤.

- 5. MPNP-DDIëŠ” ë²¤ì¹˜ë§ˆí¬ ë°ì´í„°ì…‹ì—ì„œ ìµœì²¨ë‹¨ ê¸°ì¤€ì„ ëŠ¥ê°€í•˜ëŠ” ì„±ëŠ¥ì„ ë³´ì´ë©°, ì•½ë¬¼ ê°ì‹œ ë° ì •ë°€ ì˜í•™ì— ìœ ìš©í•œ ë„êµ¬ë¡œ ìë¦¬ ì¡ìŠµë‹ˆë‹¤.

---

*Generated on 2025-09-22 13:50:13*